Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans
There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Uri...
Saved in:
| Published in | Hepatology (Baltimore, Md.) Vol. 60; no. 4; pp. 1291 - 1301 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wolters Kluwer Health, Inc
01.10.2014
Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0270-9139 1527-3350 1527-3350 |
| DOI | 10.1002/hep.27264 |
Cover
| Abstract | There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case‐control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance (1H‐NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78‐0.94), 0.93 (0.89‐0.97), and 0.89 (0.80‐0.98) in the training set and 0.81 (0.73‐0.89), 0.96 (0.94‐0.99), and 0.90 (0.85‐0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole‐3‐acetate, galactose, and an N‐acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8‐94.2]) and specificity (90.3% [74.2‐98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1‐methylnicotinamide, methionine, acetylcarnitine, 2‐oxoglutarate, choline, and creatine. Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. (Hepatology 2014;60:1291–1301) |
|---|---|
| AbstractList | There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance (1H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel=0.72; AFP=0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine. Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. (Hepatology 2014;60:1291-1301) [PUBLICATION ABSTRACT] There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance ((1) H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine. The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance ( super(1)H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel=0.72; AFP=0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine. Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. (Hepatology 2014; 60:1291-1301) There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance ((1) H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine.Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance ((1) H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine.UNLABELLEDThere is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case-control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance ((1) H-NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78-0.94), 0.93 (0.89-0.97), and 0.89 (0.80-0.98) in the training set and 0.81 (0.73-0.89), 0.96 (0.94-0.99), and 0.90 (0.85-0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole-3-acetate, galactose, and an N-acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8-94.2]) and specificity (90.3% [74.2-98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1-methylnicotinamide, methionine, acetylcarnitine, 2-oxoglutarate, choline, and creatine.The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP.CONCLUSIONThe urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose. Here, we determined the diagnostic performance of a panel of urinary metabolites of HCC patients from West Africa. Urine samples were collected from Nigerian and Gambian patients recruited on the case‐control platform of the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) program. Urinary proton nuclear magnetic resonance (1H‐NMR) spectroscopy was used to metabolically phenotype 290 subjects: 63 with HCC; 32 with cirrhosis (Cir); 107 with noncirrhotic liver disease (DC); and 88 normal control (NC) healthy volunteers. Urine samples from a further cohort of 463 subjects (141 HCC, 56 Cir, 178 DC, and 88 NC) were analyzed, the results of which validated the initial cohort. The urinary metabotype of patients with HCC was distinct from those with Cir, DC, and NC with areas under the receiver operating characteristic (AUROC) curves of 0.86 (0.78‐0.94), 0.93 (0.89‐0.97), and 0.89 (0.80‐0.98) in the training set and 0.81 (0.73‐0.89), 0.96 (0.94‐0.99), and 0.90 (0.85‐0.96), respectively, in the validation cohort. A urinary metabolite panel, comprising inosine, indole‐3‐acetate, galactose, and an N‐acetylated amino acid (NAA), showed a high sensitivity (86.9% [75.8‐94.2]) and specificity (90.3% [74.2‐98.0]) in the discrimination of HCC from cirrhosis, a finding that was corroborated in a validation cohort (AUROC: urinary panel = 0.72; AFP = 0.58). Metabolites that were significantly increased in urine of HCC patients, and which correlated with clinical stage of HCC, were NAA, dimethylglycine, 1‐methylnicotinamide, methionine, acetylcarnitine, 2‐oxoglutarate, choline, and creatine. Conclusion: The urinary metabotyping of this West African cohort identified and validated a metabolite panel that diagnostically outperforms serum AFP. (Hepatology 2014;60:1291–1301) |
| Author | Thillainayagam, Andrew V. Holmes, Elaine Dona, Anthony C. Taal, Makie Lemoine, Maud Njie, Ramou Nicholson, Jeremy K. Kasstan, Ben Ladep, Nimzing G. Duguru, Mary Khan, Shahid A. Shimakawa, Yusuke Banwat, Edmund Garside, Deborah A. Fye, Haddy K.S. Chetwood, John Lewis, Matthew R. Okeke, Edith Thursz, Mark R. Taylor‐Robinson, Simon D. Njai, Harr F. Wijeyesekera, Anisha Crossey, Mary M.E. |
| Author_xml | – sequence: 1 givenname: Nimzing G. surname: Ladep fullname: Ladep, Nimzing G. organization: Imperial College London – sequence: 2 givenname: Anthony C. surname: Dona fullname: Dona, Anthony C. organization: Imperial College London – sequence: 3 givenname: Matthew R. surname: Lewis fullname: Lewis, Matthew R. organization: Imperial College London – sequence: 4 givenname: Mary M.E. surname: Crossey fullname: Crossey, Mary M.E. organization: Imperial College London – sequence: 5 givenname: Maud surname: Lemoine fullname: Lemoine, Maud organization: Medical Research Council (The Gambia Unit) – sequence: 6 givenname: Edith surname: Okeke fullname: Okeke, Edith organization: Jos University Teaching Hospital, Plateau State – sequence: 7 givenname: Yusuke surname: Shimakawa fullname: Shimakawa, Yusuke organization: Medical Research Council (The Gambia Unit) – sequence: 8 givenname: Mary surname: Duguru fullname: Duguru, Mary organization: Jos University Teaching Hospital, Plateau State – sequence: 9 givenname: Harr F. surname: Njai fullname: Njai, Harr F. organization: Medical Research Council (The Gambia Unit) – sequence: 10 givenname: Haddy K.S. surname: Fye fullname: Fye, Haddy K.S. organization: Medical Research Council (The Gambia Unit) – sequence: 11 givenname: Makie surname: Taal fullname: Taal, Makie organization: Royal Victoria Teaching Hospital, Independence Drive – sequence: 12 givenname: John surname: Chetwood fullname: Chetwood, John organization: Imperial College London – sequence: 13 givenname: Ben surname: Kasstan fullname: Kasstan, Ben organization: Imperial College London – sequence: 14 givenname: Shahid A. surname: Khan fullname: Khan, Shahid A. organization: Imperial College London – sequence: 15 givenname: Deborah A. surname: Garside fullname: Garside, Deborah A. organization: Imperial College London – sequence: 16 givenname: Anisha surname: Wijeyesekera fullname: Wijeyesekera, Anisha organization: Imperial College London – sequence: 17 givenname: Andrew V. surname: Thillainayagam fullname: Thillainayagam, Andrew V. organization: Imperial College London – sequence: 18 givenname: Edmund surname: Banwat fullname: Banwat, Edmund organization: Jos University Teaching Hospital, Plateau State – sequence: 19 givenname: Mark R. surname: Thursz fullname: Thursz, Mark R. organization: Imperial College London – sequence: 20 givenname: Jeremy K. surname: Nicholson fullname: Nicholson, Jeremy K. organization: Imperial College London – sequence: 21 givenname: Ramou surname: Njie fullname: Njie, Ramou organization: Medical Research Council (The Gambia Unit) – sequence: 22 givenname: Elaine surname: Holmes fullname: Holmes, Elaine organization: Imperial College London – sequence: 23 givenname: Simon D. surname: Taylor‐Robinson fullname: Taylor‐Robinson, Simon D. organization: Imperial College London |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24923488$$D View this record in MEDLINE/PubMed https://pasteur.hal.science/pasteur-02875319$$DView record in HAL |
| BookMark | eNqF0U1v1DAQBmALFdFt4cAfQJa4UKS0_siHfVyVtou0UjmAOFoTx2FdJXawk63239fbLCBVQC_2wY9HM--coCPnnUHoLSXnlBB2sTHDOatYmb9AC1qwKuO8IEdoQVhFMkm5PEYnMd4RQmTOxCt0zHLJeC7EArlPNmq_NWGHwTV4C51tYLTeYd_iKVgH6aU3I9R-3A0m4tYHPG4Mbiz8cD7auIepARi9Nl03dRCwhqCt8z1g6_B3E0e8bIPV4OJr9LKFLpo3h_sUfbu--nq5yta3N58vl-tMF7LIM01Zo3PKecPruuJclA2YKpcttK3JOa8bzUuuqWSVFLQqCRQiPQnGZA1ca36KPs51JzfA7h66Tg3B9mkYRYnah6ZSz-oxtISzGW_gD_Ng1Wq5VgPE0UxBESaqglO5pcl_mP0Q_M8pjaf6FGIaHpzxU1RUSCoKko7naVGWlKTKJNH3T-idn4JLKe1VTtJOpUzq3UFNdW-a3-3-2mgCFzPQwccYTKu0HR83Ogaw3V_HP3vy439RHarf287s_g3V6urL_OMBCVLO-w |
| CODEN | HPTLD9 |
| CitedBy_id | crossref_primary_10_3748_wjg_v22_i16_4191 crossref_primary_10_1093_aje_kwy017 crossref_primary_10_1111_odi_13209 crossref_primary_10_1186_s12910_015_0030_z crossref_primary_10_1007_s00216_021_03281_z crossref_primary_10_4254_wjh_v7_i26_2664 crossref_primary_10_1016_j_jdiacomp_2016_04_019 crossref_primary_10_1016_j_jceh_2015_10_006 crossref_primary_10_2217_hep_15_4 crossref_primary_10_1016_j_jceh_2017_03_007 crossref_primary_10_2139_ssrn_4167934 crossref_primary_10_1016_j_jceh_2016_03_003 crossref_primary_10_1016_j_jpba_2023_115869 crossref_primary_10_1002_hep_29868 crossref_primary_10_1111_apt_16676 crossref_primary_10_1016_j_jhep_2016_10_013 crossref_primary_10_3390_metabo12040357 crossref_primary_10_3390_metabo12070610 crossref_primary_10_1007_s11011_016_9906_y crossref_primary_10_1021_acs_jproteome_5b01032 crossref_primary_10_1158_1055_9965_EPI_21_0687 crossref_primary_10_2174_0113816128298875240321073907 crossref_primary_10_1186_s12957_020_01885_w crossref_primary_10_1021_acsomega_3c07424 crossref_primary_10_1007_s11011_016_9904_0 crossref_primary_10_1124_pharmrev_121_000408 crossref_primary_10_1002_hep_29561 crossref_primary_10_1371_journal_pone_0185997 crossref_primary_10_1007_s40495_016_0074_x crossref_primary_10_1016_j_placenta_2018_04_005 crossref_primary_10_1021_acs_jproteome_5b00885 crossref_primary_10_2174_2210298103666230410105139 crossref_primary_10_1177_0269216314547103 crossref_primary_10_1186_s12935_023_03092_5 crossref_primary_10_4103_ghep_ghep_12_22 crossref_primary_10_1021_acs_jproteome_7b00866 crossref_primary_10_1016_S2468_1253_22_00041_3 crossref_primary_10_1016_j_tcb_2021_11_004 crossref_primary_10_1093_qjmed_hcv050 crossref_primary_10_1016_j_biopha_2021_112217 crossref_primary_10_1038_s41598_024_55650_0 crossref_primary_10_1051_medsci_2019076 crossref_primary_10_1038_srep43326 crossref_primary_10_1177_1098612X17701010 crossref_primary_10_3389_fendo_2024_1432612 crossref_primary_10_1111_hepr_13506 crossref_primary_10_1016_S2214_109X_23_00263_2 crossref_primary_10_4254_wjh_v8_i10_471 crossref_primary_10_1038_s41598_018_32847_8 crossref_primary_10_1042_ETLS20170079 crossref_primary_10_1016_j_gendis_2020_01_014 crossref_primary_10_1002_lci2_66 crossref_primary_10_1155_2022_7840606 crossref_primary_10_3389_fcell_2021_695540 crossref_primary_10_4251_wjgo_v13_i5_351 crossref_primary_10_4254_wjh_v6_i11_783 crossref_primary_10_1093_bib_bbx170 crossref_primary_10_3389_fcell_2022_839781 crossref_primary_10_1016_j_jhep_2016_01_003 crossref_primary_10_5694_mja2_50961 crossref_primary_10_1038_nrgastro_2015_114 crossref_primary_10_3389_fphar_2022_1043970 crossref_primary_10_1038_s41585_019_0185_3 |
| Cites_doi | 10.1186/1746-1596-8-45 10.1016/j.cca.2012.12.024 10.1039/b820224a 10.1021/pr300502v 10.1002/hep.24199 10.4161/cc.22137 10.1053/j.gastro.2003.10.065 10.1038/nprot.2007.376 10.1021/ac00101a004 10.1016/j.aca.2011.02.038 10.1016/j.aca.2009.06.033 10.7314/APJCP.2012.13.9.4695 10.1021/ac048630x 10.1002/ijc.21731 10.1021/pr901058t 10.1007/s00216-011-5245-3 10.1055/s-2007-1007122 10.1007/s00216-012-5782-4 10.1002/(SICI)1099-1492(1998110)11:7<354::AID-NBM515>3.0.CO;2-N 10.1021/pr070063h 10.1016/S0168-8278(02)00297-0 10.1007/s10555-011-9334-8 10.1021/pr2005764 10.1016/j.ccr.2012.02.014 10.3322/canjclin.55.2.74 10.1016/j.taap.2004.06.031 10.1038/nature11708 10.1021/pr101096f 10.1053/j.gastro.2007.04.061 10.1007/s12603-009-0204-9 10.1038/nrc3162 |
| ContentType | Journal Article |
| Copyright | 2014 by the American Association for the Study of Liver Diseases 2014 by the American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2014 by the American Association for the Study of Liver Diseases – notice: 2014 by the American Association for the Study of Liver Diseases. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC ADTOC UNPAY |
| DOI | 10.1002/hep.27264 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Hyper Article en Ligne (HAL) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1527-3350 |
| EndPage | 1301 |
| ExternalDocumentID | oai:durham-repository.worktribe.com:1412475 oai:HAL:pasteur-02875319v1 3438923201 24923488 10_1002_hep_27264 HEP27264 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UP_A900_1120 – fundername: Medical Research Council grantid: MC_PC_12015 |
| GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABJNI ACZKN ADSXY AEFGJ AFNMH AGQPQ AGXDD AHQVU AIDQK AIDYY AIQQE CITATION MEWTI WXSBR CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 1XC ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5954-c12dc4133d3bb73386dae749faffe433bdc363c1927981760a58aff8229ba3cc3 |
| IEDL.DBID | DR2 |
| ISSN | 0270-9139 1527-3350 |
| IngestDate | Fri Oct 03 06:24:10 EDT 2025 Tue Oct 14 20:08:17 EDT 2025 Fri Jul 11 10:59:34 EDT 2025 Fri Jul 11 08:04:42 EDT 2025 Tue Oct 07 06:10:52 EDT 2025 Mon Jul 21 06:05:52 EDT 2025 Wed Oct 01 04:13:10 EDT 2025 Thu Apr 24 22:53:41 EDT 2025 Wed Jan 22 16:44:52 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2014 by the American Association for the Study of Liver Diseases. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5954-c12dc4133d3bb73386dae749faffe433bdc363c1927981760a58aff8229ba3cc3 |
| Notes | This study was funded by the European Union Framework 7 programme (PROLIFICA: Prevention of Fibrosis and Liver Cancer in Africa). N.G.L. was supported by a fellowship from the Trustees of the London Clinic, London, UK and by the British Medical Research Council ICIC scheme. M.M.E.C. was supported by a fellowship (Halley Stewart Foundation, Cambridge, United Kingdom). Potential conflict of interest: Nothing to report. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1322-5765 0000-0002-4198-4785 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://durham-repository.worktribe.com/output/1412475 |
| PMID | 24923488 |
| PQID | 1564033599 |
| PQPubID | 996352 |
| PageCount | 11 |
| ParticipantIDs | unpaywall_primary_10_1002_hep_27264 hal_primary_oai_HAL_pasteur_02875319v1 proquest_miscellaneous_1891850918 proquest_miscellaneous_1566108750 proquest_journals_1564033599 pubmed_primary_24923488 crossref_citationtrail_10_1002_hep_27264 crossref_primary_10_1002_hep_27264 wiley_primary_10_1002_hep_27264_HEP27264 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2014 |
| PublicationDateYYYYMMDD | 2014-10-01 |
| PublicationDate_xml | – month: 10 year: 2014 text: October 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Hepatology (Baltimore, Md.) |
| PublicationTitleAlternate | Hepatology |
| PublicationYear | 2014 |
| Publisher | Wolters Kluwer Health, Inc Wiley-Blackwell |
| Publisher_xml | – name: Wolters Kluwer Health, Inc – name: Wiley-Blackwell |
| References | 2002; 37 2004; 127 2004; 126 2010; 19 2011; 53 2011; 11 2011; 10 2011; 691 2012; 13 2013; 8 2006; 118 2012; 56 2012; 403 2012; 11 2012; 31 2007; 37 2012; 491 2011; 401 2009; 13 1999; 19 2013; 418 2007; 132 1995; 67 2005; 204 2007; 6 2009; 5 2007; 2 2007; 1 2009; 648 2005; 55 2005; 77 2012; 21 1998; 11 2010; 9 Ferenci (R3-22-20250207) 2010; 19 Shariff (R31-22-20250207) 2010; 9 Heinzmann (R38-22-20250207) 2012; 11 Glunde (R33-22-20250207) 2011; 11 Nicholson (R10-22-20250207) 2012; 491 Shariff (R21-22-20250207) 2011; 10 Ye (R17-22-20250207) 2012; 11 Bollard (R25-22-20250207) 2005; 204 ElSerag (R6-22-20250207) 2004; 126 Wang (R18-22-20250207) 2013; 418 Shariff (R20-22-20250207) 2010; 9 Polanski (R28-22-20250207) 2007; 1 Khan (R4-22-20250207) 2002; 37 Wu (R16-22-20250207) 2009; 648 Chen (R13-22-20250207) 2011; 10 Macuks (R29-22-20250207) 2012; 13 Costello (R36-22-20250207) 2012; 31 Ward (R35-22-20250207) 2012; 21 Cao (R11-22-20250207) 2011; 691 Beckonert (R24-22-20250207) 2007; 2 Pahor (R37-22-20250207) 2009; 13 Bruix (R19-22-20250207) 2011; 53 Llovet (R23-22-20250207) 1999; 19 Parkin (R1-22-20250207) 2006; 118 Dong (R30-22-20250207) 2013; 8 MartinezOutschoorn (R32-22-20250207) 2012; 11 Cloarec (R27-22-20250207) 2005; 77 Chen (R12-22-20250207) 2011; 401 Yin (R14-22-20250207) 2009; 5 Zhou (R15-22-20250207) 2012; 403 ElSerag (R5-22-20250207) 2007; 132 Yang (R9-22-20250207) 2007; 6 Bell (R34-22-20250207) 1998; 11 Parkin (R2-22-20250207) 2005; 55 Nicholson (R26-22-20250207) 1995; 67 |
| References_xml | – volume: 11 start-page: 3964 year: 2012 end-page: 3971 article-title: Ketone body utilization drives tumor growth and metastasis publication-title: Cell Cycle – volume: 132 start-page: 2557 year: 2007 end-page: 2576 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis publication-title: Gastroenterology – volume: 10 start-page: M110 year: 2011 article-title: Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma publication-title: Mol Cell Proteomics – volume: 9 start-page: 1096 year: 2010 end-page: 1103 article-title: Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population publication-title: J Proteome Res – volume: 648 start-page: 98 year: 2009 end-page: 104 article-title: Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry publication-title: Anal Chim Acta – volume: 127 start-page: S108 issue: 5 Suppl. 1 year: 2004 end-page: S112 article-title: Alpha‐fetoprotein and ultrasonography screening for hepatocellular carcinoma publication-title: Gastroenterology – volume: 13 start-page: 724 year: 2009 end-page: 728 article-title: Sarcopenia: clinical evaluation, biological markers and other evaluation tools publication-title: J Nutr Health Aging – volume: 56 start-page: 908 year: 2012 end-page: 943 article-title: management of hepatocellular carcinoma publication-title: J Hepatol – volume: 13 start-page: 4695 year: 2012 end-page: 4698 article-title: Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case‐control study publication-title: Asian Pac J Cancer Prev – volume: 55 start-page: 74 year: 2005 end-page: 108 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin – volume: 21 start-page: 297 year: 2012 end-page: 308 article-title: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate publication-title: Cancer Cell – volume: 53 start-page: 1020 year: 2011 end-page: 1022 article-title: Management of hepatocellular carcinoma: an update publication-title: Hepatology – volume: 11 start-page: 643 year: 2012 end-page: 655 article-title: Stability and robustness of human metabolic phenotypes in response to sequential food challenges publication-title: J Proteome Res – volume: 19 start-page: 311 year: 2010 end-page: 317 article-title: World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective publication-title: J Gastrointestin Liver Dis – volume: 204 start-page: 135 year: 2005 end-page: 151 article-title: Comparative metabonomics of differential hydrazine toxicity in the rat and mouse publication-title: Toxicol Appl Pharmacol – volume: 67 start-page: 793 year: 1995 end-page: 811 article-title: 750 MHz 1H and 1H‐13C NMR spectroscopy of human blood plasma publication-title: Anal Chem – volume: 403 start-page: 203 year: 2012 end-page: 213 article-title: Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases publication-title: Anal Bioanal Chem – volume: 6 start-page: 2605 year: 2007 end-page: 2614 article-title: Metabonomic studies of human hepatocellular carcinoma using high‐resolution magic‐angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis publication-title: J Proteome Res – volume: 11 start-page: 4361 year: 2012 end-page: 4372 article-title: Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography‐mass spectrometry publication-title: J Proteome Res – volume: 19 start-page: 329 year: 1999 end-page: 338 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis – volume: 691 start-page: 68 year: 2011 end-page: 75 article-title: Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography‐mass spectrometry publication-title: Anal Chim Acta – volume: 401 start-page: 1899 year: 2011 end-page: 1904 article-title: Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry‐based metabonomic method publication-title: Anal Bioanal Chem – volume: 37 start-page: 806 year: 2002 end-page: 813 article-title: Changing international trends in mortality rates for liver, biliary and pancreatic tumours publication-title: J Hepatol – volume: 2 start-page: 2692 year: 2007 end-page: 2703 article-title: Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts publication-title: Nat Protoc – volume: 77 start-page: 1282 year: 2005 end-page: 1289 article-title: Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets publication-title: Anal Chem – volume: 8 start-page: 45 year: 2013 article-title: The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer publication-title: Diagn Pathol – volume: 5 start-page: 868 year: 2009 end-page: 876 article-title: A metabonomic study of hepatitis B‐induced liver cirrhosis and hepatocellular carcinoma by using RP‐LC and HILIC coupled with mass spectrometry publication-title: Mol Biosyst – volume: 126 start-page: 460 year: 2004 end-page: 468 article-title: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma publication-title: Gastroenterology – volume: 418 start-page: 86 year: 2013 end-page: 90 article-title: Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra‐performance liquid‐chromatography coupled with high‐definition mass spectrometry publication-title: Clin Chim Acta – volume: 37 start-page: S88 issue: Suppl. 2 year: 2007 end-page: S94 article-title: Epidemiology of hepatocellular carcinoma in USA publication-title: Hepatol Res – volume: 1 start-page: 1 year: 2007 end-page: 48 article-title: A list of candidate cancer biomarkers for targeted proteomics publication-title: Biomark Insights – volume: 118 start-page: 3030 year: 2006 end-page: 3044 article-title: The global health burden of infection‐associated cancers in the year 2002 publication-title: Int J Cancer – volume: 10 start-page: 1828 year: 2011 end-page: 1836 article-title: Urinary metabolic biomarkers of hepatocellular carcinoma in an egyptian population: a validation study publication-title: J Proteome Res – volume: 491 start-page: 384 year: 2012 end-page: 392 article-title: Metabolic phenotyping in clinical and surgical environments publication-title: Nature – volume: 11 start-page: 835 year: 2011 end-page: 848 article-title: Choline metabolism in malignant transformation publication-title: Nat Rev Cancer – volume: 11 start-page: 354 year: 1998 end-page: 359 article-title: Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours publication-title: NMR Biomed – volume: 31 start-page: 123 year: 2012 end-page: 130 article-title: The genetic/metabolic transformation concept of carcinogenesis publication-title: Cancer Metastasis Rev – volume: 8 start-page: 45 year: 2013 ident: R30-22-20250207 article-title: The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. publication-title: Diagn Pathol doi: 10.1186/1746-1596-8-45 – volume: 418 start-page: 86 year: 2013 ident: R18-22-20250207 article-title: Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultraperformance liquidchromatography coupled with highdefinition mass spectrometry. publication-title: Clin Chim Acta doi: 10.1016/j.cca.2012.12.024 – volume: 5 start-page: 868 year: 2009 ident: R14-22-20250207 article-title: A metabonomic study of hepatitis Binduced liver cirrhosis and hepatocellular carcinoma by using RPLC and HILIC coupled with mass spectrometry. publication-title: Mol Biosyst doi: 10.1039/b820224a – volume: 11 start-page: 4361 year: 2012 ident: R17-22-20250207 article-title: Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatographymass spectrometry. publication-title: J Proteome Res doi: 10.1021/pr300502v – volume: 53 start-page: 1020 year: 2011 ident: R19-22-20250207 article-title: Management of hepatocellular carcinoma: an update. publication-title: Hepatology doi: 10.1002/hep.24199 – volume: 11 start-page: 3964 year: 2012 ident: R32-22-20250207 article-title: Ketone body utilization drives tumor growth and metastasis. publication-title: Cell Cycle doi: 10.4161/cc.22137 – volume: 126 start-page: 460 year: 2004 ident: R6-22-20250207 article-title: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. publication-title: Gastroenterology doi: 10.1053/j.gastro.2003.10.065 – volume: 2 start-page: 2692 year: 2007 ident: R24-22-20250207 article-title: Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. publication-title: Nat Protoc doi: 10.1038/nprot.2007.376 – volume: 67 start-page: 793 year: 1995 ident: R26-22-20250207 article-title: 750 MHz 1H and 1H13C NMR spectroscopy of human blood plasma. publication-title: Anal Chem doi: 10.1021/ac00101a004 – volume: 1 start-page: 1 year: 2007 ident: R28-22-20250207 article-title: A list of candidate cancer biomarkers for targeted proteomics. publication-title: Biomark Insights – volume: 691 start-page: 68 year: 2011 ident: R11-22-20250207 article-title: Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatographymass spectrometry. publication-title: Anal Chim Acta doi: 10.1016/j.aca.2011.02.038 – volume: 648 start-page: 98 year: 2009 ident: R16-22-20250207 article-title: Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatographymass spectrometry. publication-title: Anal Chim Acta doi: 10.1016/j.aca.2009.06.033 – volume: 13 start-page: 4695 year: 2012 ident: R29-22-20250207 article-title: Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a casecontrol study. publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2012.13.9.4695 – volume: 77 start-page: 1282 year: 2005 ident: R27-22-20250207 article-title: Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. publication-title: Anal Chem doi: 10.1021/ac048630x – volume: 118 start-page: 3030 year: 2006 ident: R1-22-20250207 article-title: The global health burden of infectionassociated cancers in the year 2002. publication-title: Int J Cancer doi: 10.1002/ijc.21731 – volume: 9 start-page: 1096 year: 2010 ident: R20-22-20250207 article-title: Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. publication-title: J Proteome Res doi: 10.1021/pr901058t – volume: 401 start-page: 1899 year: 2011 ident: R12-22-20250207 article-title: Identification of serum biomarkers of hepatocarcinoma through liquid chromatographymass spectrometrybased metabonomic method. publication-title: Anal Bioanal Chem doi: 10.1007/s00216-011-5245-3 – volume: 19 start-page: 329 year: 1999 ident: R23-22-20250207 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification. publication-title: Semin Liver Dis doi: 10.1055/s-2007-1007122 – volume: 403 start-page: 203 year: 2012 ident: R15-22-20250207 article-title: Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. publication-title: Anal Bioanal Chem doi: 10.1007/s00216-012-5782-4 – volume: 11 start-page: 354 year: 1998 ident: R34-22-20250207 article-title: Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. publication-title: NMR Biomed doi: 10.1002/(SICI)1099-1492(1998110)11:7<354::AID-NBM515>3.0.CO;2-N – volume: 19 start-page: 311 year: 2010 ident: R3-22-20250207 article-title: World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. publication-title: J Gastrointestin Liver Dis – volume: 6 start-page: 2605 year: 2007 ident: R9-22-20250207 article-title: Metabonomic studies of human hepatocellular carcinoma using highresolution magicangle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. publication-title: J Proteome Res doi: 10.1021/pr070063h – volume: 37 start-page: 806 year: 2002 ident: R4-22-20250207 article-title: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. publication-title: J Hepatol doi: 10.1016/S0168-8278(02)00297-0 – volume: 31 start-page: 123 year: 2012 ident: R36-22-20250207 article-title: The geneticmetabolic transformation concept of carcinogenesis. publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-011-9334-8 – volume: 11 start-page: 643 year: 2012 ident: R38-22-20250207 article-title: Stability and robustness of human metabolic phenotypes in response to sequential food challenges. publication-title: J Proteome Res doi: 10.1021/pr2005764 – volume: 21 start-page: 297 year: 2012 ident: R35-22-20250207 article-title: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.02.014 – volume: 10 start-page: M110 year: 2011 ident: R13-22-20250207 article-title: Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. publication-title: Mol Cell Proteomics – volume: 55 start-page: 74 year: 2005 ident: R2-22-20250207 article-title: Global cancer statistics, 2002. publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 – volume: 204 start-page: 135 year: 2005 ident: R25-22-20250207 article-title: Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2004.06.031 – volume: 491 start-page: 384 year: 2012 ident: R10-22-20250207 article-title: Metabolic phenotyping in clinical and surgical environments. publication-title: Nature doi: 10.1038/nature11708 – volume: 10 start-page: 1828 year: 2011 ident: R21-22-20250207 article-title: Urinary metabolic biomarkers of hepatocellular carcinoma in an egyptian population: a validation study. publication-title: J Proteome Res doi: 10.1021/pr101096f – volume: 132 start-page: 2557 year: 2007 ident: R5-22-20250207 article-title: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.061 – volume: 13 start-page: 724 year: 2009 ident: R37-22-20250207 article-title: Sarcopenia: clinical evaluation, biological markers and other evaluation tools. publication-title: J Nutr Health Aging doi: 10.1007/s12603-009-0204-9 – volume: 9 start-page: 1096 year: 2010 ident: R31-22-20250207 article-title: Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. publication-title: J Proteome Res doi: 10.1021/pr901058t – volume: 11 start-page: 835 year: 2011 ident: R33-22-20250207 article-title: Choline metabolism in malignant transformation. publication-title: Nat Rev Cancer doi: 10.1038/nrc3162 |
| SSID | ssj0009428 |
| Score | 2.4094522 |
| Snippet | There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too... There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too... |
| SourceID | unpaywall hal proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1291 |
| SubjectTerms | Acetylcarnitine - urine Adolescent Adult Africa, Western - epidemiology Aged Aged, 80 and over alpha-Fetoproteins - urine Biomarkers, Tumor - urine Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - urine Case-Control Studies Choline - urine Creatine - urine Female Hepatology Humans Ketoglutaric Acids - urine Life Sciences Liver cancer Liver cirrhosis Liver Neoplasms - diagnosis Liver Neoplasms - epidemiology Liver Neoplasms - urine Male Metabolites Methionine - urine Middle Aged Niacinamide - analogs & derivatives Niacinamide - urine Phenotype Reproducibility of Results Santé publique et épidémiologie Sarcosine - analogs & derivatives Sarcosine - urine Sensitivity and Specificity Urine Young Adult |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB61W4nHgWeBQEHmIdRLttk4iZPjClqtEK16YEU5RbbjaCN2k2iTgMqvZyYvqTwquK3kURTHM_bnmdnvA3gThjzwQqVsY_C66mkhbRWEeFXRaSoSkuJutQFPz4LF0vtw4V_sQDD8FyZptiu5sSlhXmVUZp5SfxKJP3W5paKpy6Y-mpFosvB3YS_wEYNPYG95dj7_0iZUhEPl5KglSnUxgrjvDJRCjnu0MuXUFW7gXTmIdlfUBvk7xrwNN5u8lJff5Xp9Fb6258_JXfg8vHnXdvJ12tRqqn_8Qur4_1O7B3d6SMrmnQ_dhx2TP4Abp33R_SHk77NKU6fnJZN5wtA1s06IiRUpo2S9xJGNqdGdKKFbMcTBDHElS7o2vqwiQ_wieL-nOgE1vjJNGkZ5sZEsyxnJ27BOsSiv9mF5cvzp3cLuZRps7Ue-Z-uZm2g8C3nClRJ45Q0SaYQXpTJNjce5SjQPuEYoKaJwJgJH-iEOEdO8klxr_ggmeZGbJ8B8TyFeSKha63qJYxTuvohAuDJCOEZICw6HNYt1z2FOUhrruGNfdmOcTNwurwWvRtOyI-74k9FbXPhxnKi2F_OPcSkxwpptjNhL0B71bWbBweAbcR_kVUw8Ow66VxRZ8HIcxvCkbylzUzStDQJUfIxzjU0YIWpC4BZa8Ljzu_GViNCR4yZrwevREa-bz2Hron-3iBfH5-2Pp__0wGdwCxGi13UvHsCk3jbmOaKwWr3oQ-4nAt4yLw priority: 102 providerName: Unpaywall |
| Title | Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.27264 https://www.ncbi.nlm.nih.gov/pubmed/24923488 https://www.proquest.com/docview/1564033599 https://www.proquest.com/docview/1566108750 https://www.proquest.com/docview/1891850918 https://pasteur.hal.science/pasteur-02875319 https://durham-repository.worktribe.com/output/1412475 |
| UnpaywallVersion | submittedVersion |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1527-3350 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0009428 issn: 1527-3350 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1527-3350 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1527-3350 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009428 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB7SFHo89G7iNg3qQcmLN17Ltmz6tLQJS2lCKF1IoWAkWSZLN9olXrekv74zktchPULpm0HjQ9LM6Btp_A3AqzznWZIrFRqD4WqihQxVlmOooutaVFSK29UGPDjMxpPk_XF6vAZvVv_CeH6IfsONLMP5azJwqZrdC9LQE7MYxALXc_S_Q565cOrjBXVUkbi6qhh1RXS6XKxYhaJ4t7_z0lp07YQyIX-HmbfhZmsX8vy7nM0uI1i3BO3fhS-rj_eZJ18H7VIN9I9feB3_s3f34E4HTdnI69J9WDP2Adw46A7fH4J9N200ZXyeM2krhio69QWZ2LxmtGmPb2OnZolqRRu7DUM8zBBfssqn800bEsRXYpxP5wWUAMs01TKy81PJppZRmRvmKxfZ5hFM9vc-vR2HXbmGUKdFmoR6GFca10RecaUEhr5ZJY1IilrWtUk4V5XGadIIKUWRD0UWyTTHJmKcV5JrzR_Dup1bswksTRTihopObeOkioxCL4xIhCsjRGSEDGBnNXGl7rjMqaTGrPQszHGJnSnd-AXwohddeAKPPwm9xtnv24lyezz6UC4kWlp7ViIGE-Srvg0D2FopSNkZe1MS307EeVoUATzvm9FMaSylNfPWySBQxcdEV8jkBaInBHB5ABte-fpPImJHjs42gJe9Nl7Vnx2nXH-XKMd7R-7iyb-LPoVbCBcTn8q4BevLs9Y8Q0i2VNvO9rbh-uTwaPT5J5m6Mug |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB61RaLwwE0bKGAOob5km107cSLxUkGrALsVQq3UF2TZjqOu2GZXzQZUfj0zuapyVIi3SJ4cTmbsb-zJ9wG8imMeidgY3zlMV4WV2jdRjKmKzXOZkRR3rQ04OYjSI_HhODxegTfdvzANP0S_4EaRUY_XFOC0IL1zwRp64haDkcQJfRWuiQjzFIJEny_IoxJRK6ti3hXQ_nLS8QoFo53-1Euz0eoJ1UL-DjRvwnpVLPT5dz2bXcaw9SS0fxu-dI_f1J58HVRLM7A_fmF2_N_-3YFbLTplu4073YUVV9yD65N2__0-FO-mpaWiz3Omi4yhl04bTSY2zxmt2-Pt2KlbomfR2m7JEBIzhJgsayr6piUZ4i0x1actA6qBZZbkjIr5qWbTgpHSDWvEi4ryARzt7x2-Tf1WscG3YRIK3w5HmcVpkWfcGInZb5RpJ0WS6zx3gnOTWR5xi6hSJvFQRoEOY2wi0nmjubX8IawV88JtAguFQeiQ0cbtSGSBMzgQIxjhxkkZOKk92O6-nLItnTmpasxUQ8Q8UtgZVb8_D170pouGw-NPRq_x8_ftxLqd7o7VQmOwVWcKYZik4erb0IOtzkNUG--lIsqdgPMwSTx43jdjpNK71IWbV7UNYlW8THCFTZwggEIMF3uw0Xhf_0jE7chxvPXgZe-OV_Vnu_auv1uodO9TffDo302fwXp6OBmr8fuDj4_hBqJH0VQ2bsHa8qxyTxChLc3TOhB_AhFJNVk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB61RSrwwH0ECphDqC_ZZmMnTiReKrarBdqqQlTqS2XZjqOu2GajZgMqv56ZZJOqHBXiLZInh5MZ-xt78n0Ab5KExyIxxncO01VhpfZNnGCqYvNcZiTF3WgD7u3Hk0Px8Sg6WoF33b8wLT9Ev-BGkdGM1xTgrszyrQvW0BNXDkKJE_oqXBNRmlBB3-jzBXlUKhplVcy7AtpfTjteoSDc6k-9NButnlAt5O9A8yZcr4tSn3_Xs9llDNtMQuPbcNw9flt78nVQL8zA_viF2fF_-3cHbi3RKdtu3ekurLjiHqzvLfff70MxmlaWij7PmS4yhl46bTWZ2DxntG6Pt2OnboGeRWu7FUNIzBBisqyt6JtWZIi3xFSftgyoBpZZkjMq5qeaTQtGSjesFS8qqgdwON758n7iLxUbfBulkfDtMMwsTos848ZIzH7jTDsp0lznuROcm8zymFtElTJNhjIOdJRgE5HOG82t5Q9hrZgX7jGwSBiEDhlt3IYiC5zBgRjBCDdOysBJ7cFm9-WUXdKZk6rGTLVEzKHCzqjm_XnwqjctWw6PPxm9xc_ftxPr9mR7V5Uag60-UwjDJA1X34YebHQeopbxXimi3Ak4j9LUg5d9M0YqvUtduHnd2CBWxcsEV9gkKQIoxHCJB49a7-sfibgdOY63Hrzu3fGq_mw23vV3CzXZOWgOnvy76QtYPxiN1e6H_U9P4QaCR9EWNm7A2uKsds8QoC3M8yYOfwJxcDTd |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB61W4nHgWeBQEHmIdRLttk4iZPjClqtEK16YEU5RbbjaCN2k2iTgMqvZyYvqTwquK3kURTHM_bnmdnvA3gThjzwQqVsY_C66mkhbRWEeFXRaSoSkuJutQFPz4LF0vtw4V_sQDD8FyZptiu5sSlhXmVUZp5SfxKJP3W5paKpy6Y-mpFosvB3YS_wEYNPYG95dj7_0iZUhEPl5KglSnUxgrjvDJRCjnu0MuXUFW7gXTmIdlfUBvk7xrwNN5u8lJff5Xp9Fb6258_JXfg8vHnXdvJ12tRqqn_8Qur4_1O7B3d6SMrmnQ_dhx2TP4Abp33R_SHk77NKU6fnJZN5wtA1s06IiRUpo2S9xJGNqdGdKKFbMcTBDHElS7o2vqwiQ_wieL-nOgE1vjJNGkZ5sZEsyxnJ27BOsSiv9mF5cvzp3cLuZRps7Ue-Z-uZm2g8C3nClRJ45Q0SaYQXpTJNjce5SjQPuEYoKaJwJgJH-iEOEdO8klxr_ggmeZGbJ8B8TyFeSKha63qJYxTuvohAuDJCOEZICw6HNYt1z2FOUhrruGNfdmOcTNwurwWvRtOyI-74k9FbXPhxnKi2F_OPcSkxwpptjNhL0B71bWbBweAbcR_kVUw8Ow66VxRZ8HIcxvCkbylzUzStDQJUfIxzjU0YIWpC4BZa8Ljzu_GViNCR4yZrwevREa-bz2Hron-3iBfH5-2Pp__0wGdwCxGi13UvHsCk3jbmOaKwWr3oQ-4nAt4yLw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+and+validation+of+urinary+metabotypes+for+the+diagnosis+of+hepatocellular+carcinoma+in+West+Africans&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Ladep%2C+Nimzing+G&rft.au=Dona%2C+Anthony+C&rft.au=Lewis%2C+Matthew+R&rft.au=Crossey%2C+Mary+M+E&rft.date=2014-10-01&rft.eissn=1527-3350&rft.volume=60&rft.issue=4&rft.spage=1291&rft_id=info:doi/10.1002%2Fhep.27264&rft_id=info%3Apmid%2F24923488&rft.externalDocID=24923488 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |